News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Merck & Co., Inc. Unit Held Liable in Australian Vioxx Case
March 5, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Merck & Co's (MRK.N) one-time blockbuster arthritis drug Vioxx doubled the risk of heart attacks and was not fit for sale, an Australian court said on Friday, in a ruling against the U.S. group's Australian unit.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Asia
Australia
Merck & Co.
MORE ON THIS TOPIC
GLP-1
Pfizer Builds Global GLP-1 Strategy With up to $495M Sciwind Deal
February 24, 2026
·
2 min read
·
Tristan Manalac
Rare disease
FDA’s Bespoke Pathway To Focus on Gene Editing and RNA-Based Treatments for Rare Diseases
February 23, 2026
·
3 min read
·
Nick Paul Taylor
Government
Kennedy Ally Departs CDC Amid Leadership Shake-Up
February 23, 2026
·
1 min read
·
Annalee Armstrong
Legal
REGENXBIO Secures Legal Win in Gene Therapy Patent Battle Vs. Sarepta
February 23, 2026
·
2 min read
·
Tristan Manalac